Health and Healthcare
Array BioPharma Slides on Secondary Offering
Published:
Last Updated:
Array BioPharma Inc. (NASDAQ: ARRY) saw its shares turn negative early on Thursday after the firm announced a secondary offering. The company offered no pricing details, but it does value the offering up to $175 million, with an overallotment option for an additional $26.25 million.
The underwriters for the offering are JPMorgan, Cowen and Piper Jaffray.
For some quick background: this is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.
The firm has eight registration studies that are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).
In the filing, the company said:
We intend to use the net proceeds from this offering to fund our research and development efforts, including clinical trials for our proprietary candidates, build and scale commercial capability, and for general corporate purposes, including general working capital purposes. We may also use a portion of the net proceeds to acquire or invest in complementary businesses, technologies, drugs, drug candidates or other intellectual property, although we have no present commitments or agreements to do so.
Shares of Array closed Wednesday up 5.6% at $10.53, with a consensus analyst price target of $14.56 and a 52-week range of $3.45 to $13.40. Following the release, the stock was initially down 6.7% at $9.82 in early trading indications Thursday.
The Average American Is Losing Their Savings Every Day (Sponsor)
If you’re like many Americans and keep your money ‘safe’ in a checking or savings account, think again. The average yield on a savings account is a paltry .4% today, and inflation is much higher. Checking accounts are even worse.
Every day you don’t move to a high-yield savings account that beats inflation, you lose more and more value.
But there is good news. To win qualified customers, some accounts are paying 9-10x this national average. That’s an incredible way to keep your money safe, and get paid at the same time. Our top pick for high yield savings accounts includes other one time cash bonuses, and is FDIC insured.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes and your money could be working for you.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
